^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ART6043
i
Other names: ART6043, ART-6043, ART 6043
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Artios Pharma
Drug class:
POLQ inhibitor
Related drugs:
2ms
ART6043C001: Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (clinicaltrials.gov)
P1/2, N=220, Active, not recruiting, Artios Pharma Ltd | Recruiting --> Active, not recruiting
Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2)
|
Lynparza (olaparib) • ART6043
over2years
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (clinicaltrials.gov)
P1/2, N=250, Recruiting, Artios Pharma Ltd | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
Lynparza (olaparib) • Talzenna (talazoparib) • ART6043
over2years
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (clinicaltrials.gov)
P1/2, N=250, Not yet recruiting, Artios Pharma Ltd
New P1/2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
Lynparza (olaparib) • Talzenna (talazoparib) • ART6043
Share via
